Diagnostics and Therapeutics Advances in Pancreatic Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: closed (30 October 2024) | Viewed by 16757
Special Issue Editors
Interests: pancreatic cancer; pancreatic surgery; robotic pancreatic resection; laparoscopic pancreatic resection; electrochemotherapy of pancreatic cancer; multimodal treatments; liver resection; laparoscopic liver resection; robotic liver resection; cholangiocarcinoma hepatocellular carcinoma; liver metastasis; chemotherapy (neoadjuvant, induction); chemoradiotherapy
Interests: oncology; screening; diagnosis; monitoring; precision medicine; radiomics
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Pancreatic cancers, and especially pancreatic ductal adenocarcinoma (PDAC), are one of the leading causes of cancer-related mortality worldwide. PDAC is characterized by its aggressive nature and dismal prognosis, with an overall 5-year survival rate of lower than 10%. Surgical resection still remains the most effective treatment but, unfortunately, is precluded from the vast majority of patients because of the metastatic or locally advanced disease status at diagnosis. Even in resected patients, long-term results are disappointing, since cancer will recur in about 80% of cases. Therefore, accurate staging at diagnosis and even more accurate restaging after neoadjuvant therapies in the case of borderline resectable patients are of crucial importance to achieve efficient prognostic stratification and offer optimal treatment to each patient. In fact, due to the high rates of systemic and/or local recurrence, various sequences of chemotherapy and radiotherapy—whether adjuvant or neoadjuvant—are administered to pancreatic cancer patients evaluated for curative intent surgery, and several therapeutic options, including radiotherapy, chemotherapy, immunotherapy, and local ablative techniques, are used for locally advanced and/or metastatic patients. We are pleased to invite you to share your experiences as part of our update on recent advancements in the diagnosis and treatment of pancreatic cancer, for which the focus will be on radiologic and endoscopic techniques as well as on therapeutic treatment options.
This Special Issue aims to provide a comprehensive overview of recent advances in terms of both innovations in the diagnosis of pancreatic cancer (including the role of radiomics, MRI, ecoendoscopy, etc.) and the most advanced surgical techniques (including laparoscopic and robotic approaches) and innovative medical and multimodal strategies used in treatment. Study protocols and the results of clinical studies and translational research are also welcome.
We look forward to receiving your contributions.
Dr. Andrea Belli
Dr. Vincenza Granata
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pancreatic cancer
- pancreatic adenocarcinoma
- IPMN
- neoadjuvant chemotherapy
- minimally invasive pancreatic resection
- robotic pancreatic resection
- radiomics
- DWI
- pancreatic electroporation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.